MicroPort Scientific is a medical equipment manufacturer and distributor. The company's products include cardiovascular, orthopedic, cardiac rhythm management, electrophysiology, endovascular, neurovascular, and surgical robots.

MicroPort Scientific

Almond Tree Capital LLC is a venture capital firm specializing in investments in startups and health technology.

Almond Tree Capital Fund

RocSon Medtech Fund

Kineticos Disruptor Fund will invest in disruptive modalities including cell therapy approaches such as CAR Ts, TCRs, TILs, gene therapy, gene editing, RNAi, immuno-oncology, and related precision medicine technologies. The Fund will focus on large, unmet medical needs in oncology, neurosciences, and rare diseases. In oncology, new approaches to solid tumors and “off the shelf” allogeneic cell therapies are immediate priorities.

Kineticos Disruptor Fund

Promaxo

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems, and MRI compatible robotics and machine learning based technologies that enhance patients' lives and redefine the standard of care. Using proprietary technologies protected by 55+ patents, the Company is bringing the first MRI and robotics guidance system for in-office use. Products in the pipeline include disposables and an AI-based tissue characterization system.

Promaxo is a medical technology company that develops and commercializes compact and adaptable MRI systems for in-office use. The company's innovative MRI platform offers a truly open, single-sided design with a limited fringe field, allowing for seamless installation in an office setting without the need for shielding or facility upgrades. Promaxo's MRI system is FDA-cleared for urologists and interventional/urologic radiologists to perform surgical localization of prostatic lesions under MRI guidance.

Promaxo Receives 510(k) Clearance from the FDA for its Innovational MRI Platform

Promaxo Announces Sale of In-Office MRI to Beverly Hills Urology

Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute

Promaxo to Showcase In-Office MRI System and Compatible Robot System in Upcoming Trade Conferences

Zynext Ventures invests in MRI systems developer Promaxo

Promaxo Announces Sale of 20 Systems in the Third Quarter 2023

About Us

Promaxo Announces Sale of In-Office MRI to Kasraeian Urology

Promaxo Announces Sale of In-Office MRI to Advanced Urology Medical Offices

Modular MRI System for Use in a Doctor's Office

Key Insights and Stats

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Promaxo Receives Investment from Zynext Ventures

Promaxo is a medical technology company that develops and commercializes compact and adaptable MRI systems for in-office use. The company's innovative MRI platform offers a truly open, single-sided design with a limited fringe field, allowing for seamless installation in an office setting without the need for shielding or facility upgrades. Promaxo's MRI system is FDA-cleared for urologists and interventional/urologic radiologists to perform surgical localization of prostatic lesions under MRI guidance.
The system leverages patented technologies to capture, reconstruct, and display magnetic resonance images of the prostate and surrounding tissues. It incorporates pre-programmed sequences and artificial intelligence to enhance image quality, making it suitable for targeted prostate biopsies and treatments such as high-intensity focused ultrasound (HIFU). Additionally, Promaxo's MRI system is compatible with conventional robotics, enabling live MRI-guided biopsies, treatment planning, robotic surgeries, radiation therapy, and ablative treatments.
As of October 2023, Promaxo has sold a total of 77 systems across 26 states since its commercial launch in the fourth quarter of 2021. In the third quarter of 2023 alone, the company sold 20 systems to various healthcare providers, including Summit Health, University Urology Associates of New Jersey, Academic Urology & Urogynecology of Arizona, and Rhode Island Hospital.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Promaxo

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless